OncoSil Medical Ltd
OSL
Company Profile
Business description
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.
Contact
7 Eden Park Drive
Level 5
Macquarie Park
SydneyNSW2113
AUST: +61 289359629
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
30 June 2026
Employees
2
Stocks News & Analysis
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
Amid robust demand for semis, watch for any impact of in-house built chips and whether the supply chain is on track.
stocks
Higher interest rates boost earnings for ASX real estate platform
Interest rates are driving a spike in property listings.
stocks
After earnings, is Palantir a buy, a sell, or fairly valued?
With uncertainty regarding its total addressable market and competitive threats, here’s what we think of Palantir stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,881.40 | 8.40 | 0.09% |
| CAC 40 | 7,979.92 | 76.46 | -0.95% |
| DAX 40 | 23,954.93 | 395.35 | -1.62% |
| Dow JONES (US) | 49,760.56 | 56.09 | 0.11% |
| FTSE 100 | 10,265.32 | 4.11 | -0.04% |
| HKSE | 26,328.00 | 19.91 | -0.08% |
| NASDAQ | 26,088.20 | 185.92 | -0.71% |
| Nikkei 225 | 63,262.94 | 520.37 | 0.83% |
| NZX 50 Index | 13,063.06 | 17.27 | -0.13% |
| S&P 500 | 7,400.96 | 11.88 | -0.16% |
| S&P/ASX 200 | 8,632.00 | 1.00 | 0.01% |
| SSE Composite Index | 4,229.42 | 14.93 | 0.35% |